Exchange: NASDAQ·Updated 04:02 AM EDT
KLRS logo

KLRS Kalaris Therapeutics

$3.20
$0.00
(0.00%)
Pre-Market
Prev Close $3.20
Reported EarningsAug 11
Mkt Cap$69.89M
Vol7.00

About KLRS

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ.
50

Neutral Sentiment

How do you feel about KLRS?

Advertisement|Remove ads.